Nordic sperm-industry leader European Sperm Bank sold one man’s semen to 67 clinics in 14 countries before discovering the straws carried a cancer-causing TP53 mutation. At least 197 children have already been born; the number is still climbing.
Copenhagen – A single Danish donor, code-name “Kjeld”, has become the centre of the largest cross-border medical product recall the Nordic region has ever seen. His semen, exported by Copenhagen-based European Sperm Bank (ESB) between 2005 and 2023, has fathered at least 197 children in 14 countries. Roughly one in three carries an inherited defect in the TP53 tumour-suppressor gene that gives up to a 90 % lifetime risk of cancer – leukaemia, brain tumours, adrenal carcinoma – and a 50 % chance of passing the mutation to the next generation. Some of the children have already died; others are in active treatment.
The story, co-published this month by DR Documentary and 13 European public-service broadcasters, raced around the globe. BBC Online’s version became the site’s most-read article within hours, logging “almost two million views” and topping the corporation’s 18:00 television bulletin. Le Figaro led its science pages with “Près de 200 enfants conçus avec le sperme d’un donneur danois porteur d’un gène cancérigène”; Singapore’s Straits Times pushed it to 2.5 million Asian subscribers; Iceland’s RÚV, Germany’s ARD, Finland’s YLE and Norway’s NRK all carried it as the day’s lead.
How the market exploded
ESB is the second-largest sperm bank in the world and the Nordic region’s dominant exporter, shipping roughly 60 % of all Danish donor semen used abroad. While Denmark introduced a 12-family national cap in 2013, the rule is not retro-active and does not bind clinics outside Denmark. Belgian law, for instance, limits a donor to six families; nevertheless 38 Belgian women conceived with Kjeld’s straws. In France, where anonymous donation is illegal, fertility tourists simply crossed the border to ESB-approved clinics in Belgium and Spain. In Germany, Denmark’s biggest customer, 14 fertility centres received the straws; the UK’s Human Fertilisation & Embryology Authority (HFEA) lists 22 British births, but admits the figure is incomplete because some women self-inseminated at home.
By 2021 paediatric oncologists in Aarhus and Leuven noticed an unusual cluster of early childhood cancers. Genetic mapping traced every case to the same donor haplotype. ESB halted sales in October 2023, but at least 35 additional pregnancies had already been achieved from frozen reserves.
The science: a “selfish” mutant clone
TP53 is the cell’s master brake on division. People who inherit one faulty copy have Li-Fraumeni syndrome; 50 % develop cancer before 30, 90 % before 60. What makes the Kjeld case unprecedented is that the mutation is present in only ~20 % of his sperm cells – a mosaic arising from a single mutated spermatogonial stem cell that out-competed normal ones. Standard donor screening (a blood test) missed it; only deep-sequencing of sperm DNA picked it up. The clone therefore expanded silently for 18 years, disseminated by a high-throughput Nordic exporter.
Regulatory vacuum
No EU statute caps the number of children a donor may produce; each member state sets its own rules. Denmark requires 12-family limits and central registration, but clinics abroad need only self-report. “We relied on honour-based returns,” ESB CEO Anne-Mette Bredahl admitted in a written reply to DR. “Unfortunately, reporting has been incomplete.” Belgian authorities estimate that Kjeld’s straws were used at least 120 % above the legal quota; in Spain, where limits are “recommendations”, one clinic alone recorded 27 births.
Commercial fall-out
ESB’s revenues, disclosed in the latest Nordic Cryo Group accounts, reached DKK 278 million (€37 m) in 2023, 68 % from export. The company is privately held by Danish private-equity fund Axcel, which had been preparing a 2025 IPO valuing the group at around DKK 2 billion. Bankers briefed by Nordic Business Journal say the timetable is now “under review” until liability exposure is clearer. Danish patient-safety law caps individual compensation at DKK 1.1 million (€147 000), but class-action lawyers in London and Brussels are exploring product-liability claims that could reach tens of millions if courts classify semen as a “defective medicinal product” under EU Directive 85/374/EEC.
Political reaction
Denmark’s health minister Sophie Løhde has asked the Danish Patient Safety Authority to audit every Nordic sperm exporter; results are due in March. Belgium has suspended ESB’s import licence pending a criminal probe into falsified clinic returns. The European Society of Human Reproduction and Embryology will debate a pan-European donor-birth registry at its annual meeting in Helsinki next July.
Market reach – the numbers
– 14 countries received Kjeld straws: Belgium, Denmark, Germany, Netherlands, UK, Sweden, Norway, Finland, France (fertility tourists), Iceland, Ireland, Austria, Switzerland and Poland.
– 67 clinics used the semen; 35 still have vials in storage.
– 197 live births confirmed; public-health modelling suggests the true figure is “very likely 250-300”, says Aarhus University epidemiologist Jorn Olsen.
– 23 mutation-carriers identified; 10 already have malignancies.
– ESB exported 2.8 % of its 2022 volume from the Kjeld batch, implying roughly one in every 40 Danish donor children born abroad that year carries the TP53 defect.
What happens next
All identified families have been offered annual whole-body MRI scans until age 40. ESB says it will finance testing and surveillance “for life”, but has not put a figure on the cost. Meanwhile, half-siblings are still locating each other via Facebook groups such as “Donor 7069 – Kjeld”. With Nordic sperm accounting for roughly one in five donor conceptions worldwide, the scandal is a wake-up call for an industry that has long marketed “Viking babies” as a premium product.